1887
  1. Home
  2. Eurosurveillance
  3. Volume 27, Issue 4, 27/Jan/2022
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

Infections with the Omicron SARS-CoV-2 variant are rapidly increasing worldwide. Among 174,349 SARS-CoV-2-infected individuals (≥ 12 years), we observed an increased risk of S gene target failure, predictive of the Omicron variant, in vaccinated (odds ratio (OR): 3.6; 95% confidence interval (CI): 3.4–3.7) and previously infected individuals (OR: 4.2; 95% CI: 3.8–4.7) compared with infected naïve individuals. This suggests vaccine- or infection-induced immunity against SARS-CoV-2 infections is less effective against the Omicron than the Delta variant.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2022.27.4.2101196
2022-01-27
2024-12-21
/content/10.2807/1560-7917.ES.2022.27.4.2101196
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/27/4/eurosurv-27-4-2.html?itemId=/content/10.2807/1560-7917.ES.2022.27.4.2101196&mimeType=html&fmt=ahah

References

  1. World Health Organization (WHO). Tracking SARS-CoV-2 variants. Geneva: WHO. [Accessed: 30 Dec 2021]. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants
  2. European Centre for Disease Prevention and Control (ECDC). Epidemiological update: Omicron variant of concern (VOC) – data as of 16 December 2021 (12:00). Stockholm: ECDC; 2021. Available from: https://www.ecdc.europa.eu/en/news-events/epidemiological-update-omicron-data-16-december
  3. Barnard RC, Davies N, Pearson CAB, Jit M, Edmunds J. Modelling the potential consequences of the Omicron SARS-CoV-2 variant in England | Centre for Mathematical Modelling of Infectious Diseases Repository. London: London School of Hygiene & Tropical Medicine; 2021. Preprint. Available from: https://cmmid.github.io/topics/covid19/omicron-england.html
  4. European Centre for Disease Prevention and Control (ECDC). Weekly epidemiological update: Omicron variant of concern (VOC) – week 2 (data as of 20 January 2022) EU/EEA. Stockholm: ECDC; 2022. Available from: https://www.ecdc.europa.eu/en/news-events/weekly-epidemiological-update-omicron-variant-concern-voc-week-2-data-20-january-2022
  5. Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2021.  https://doi.org/10.1038/s41586-021-04387-1  PMID: 35016196 
  6. Callaway E. Heavily mutated Omicron variant puts scientists on alert. Nature. 2021;600(7887):21-21.  https://doi.org/10.1038/d41586-021-03552-w  PMID: 34824381 
  7. Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, et al. Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies. medRxiv.2021.12.07.21267432. preprint. https://doi.org/ https://doi.org/10.1101/2021.12.07.21267432 
  8. World Health Organization (WHO). Guidance on conducting vaccine effectiveness evaluations in the setting of new SARS-CoV-2 variants: Interim guidance, 22 July 2021. Addendum to Evaluation of COVID-19 vaccine effectiveness. Geneva: WHO: 2021. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccine_effectiveness-variants-2021.1
  9. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021;593(7858):266-9.  https://doi.org/10.1038/s41586-021-03470-x  PMID: 33767447 
  10. Borges V, Sousa C, Menezes L, Gonçalves AM, Picão M, Almeida JP, et al. Tracking SARS-CoV-2 lineage B.1.1.7 dissemination: insights from nationwide spike gene target failure (SGTF) and spike gene late detection (SGTL) data, Portugal, week 49 2020 to week 3 2021. Euro Surveill. 2021;26(10):2100131.  https://doi.org/10.2807/1560-7917.ES.2021.26.10.2100130  PMID: 33706862 
  11. Washington NL, Gangavarapu K, Zeller M, Bolze A, Cirulli ET, Schiabor Barrett KM, et al. Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. Cell. 2021;184(10):2587-2594.e7.  https://doi.org/10.1016/j.cell.2021.03.052  PMID: 33861950 
  12. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England, Technical briefing 33. London: UK Health Security Agency; 2021. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1043807/technical-briefing-33.pdf
  13. Garcia-Beltran WF, St Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022;S0092-8674(21)01496-3.  https://doi.org/10.1016/j.cell.2021.12.033  PMID: 34995482 
  14. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. medRxiv.2021.12.14.21267615. preprint.  https://doi.org/10.1101/2021.12.14.21267615 
  15. Hansen CH, Schelde AB, Moustsen-Helm IR, Emborg H-D, Krause TG, Mølbak K, et al. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study. medRxiv.2021.12.20.21267966. preprint.  https://doi.org/10.1101/2021.12.20.21267966  https://doi.org/10.1101/2021.12.20.21267966 
  16. Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants. medRxiv.2022.01.07.22268919. preprint.  https://doi.org/10.1101/2022.01.07.22268919  https://doi.org/10.1101/2022.01.07.22268919 
  17. Sheikh A, Kerr S, Woolhouse M, Mcmenamin J, Robertson C. Severity of Omicron variant of concern and vaccine effectiveness against symptomatic disease: national cohort with nested test negative design study in Scotland. Edinburgh: University of Edinburgh; 2021. Preprint. Available from: https://www.research.ed.ac.uk/en/publications/severity-of-omicron-variant-of-concern-and-vaccine-effectiveness-
  18. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation - Technical briefing 34. London: UK Health Security Agency; 2022. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1048395/technical-briefing-34-14-january-2022.pdf
  19. Thompson MG, Natarajan K, Irving SA, Rowley EA, Griggs EP, Gaglani M, et al. Effectiveness of a third dose of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance — VISION Network, 10 States, August 2021–January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4).  https://doi.org/10.15585/mmwr.mm7104e3 
  20. UK Health Security Agency. COVID-19 vaccine surveillance report - week 3. London: UK Health Security Agency; 2022. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1049160/Vaccine-surveillance-report-week-3-2022.pdf
  21. Andeweg SP, Vennema H, Veldhuijzen I, Smorenburg N, Schmitz D, Zwagemaker F, et al. Increased risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variant compared to Alpha variant in vaccinated individuals. medRxiv.2021.11.24.21266735. preprint.  https://doi.org/10.1101/2021.11.24.21266735 
  22. Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. medRxiv.2021.11.11.21266068. preprint.  https://doi.org/10.1101/2021.11.11.21266068 
  23. Head E, van Elsland SL. Omicron largely evades immunity from past infection or two vaccine doses. London: Imperial College; 2021. Available from: https://www.imperial.ac.uk/news/232698/modelling-suggests-rapid-spread-omicron-england
  24. Altarawneh H, Chemaitelly H, Tang P, Hasan MR, Qassim S, Ayoub HH, et al. Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant. medRxiv.2022.01.05.22268782. preprint.  https://doi.org/10.1101/2022.01.05.22268782 
  25. Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California. medRxiv.2022.01.11.22269045. preprint.  https://doi.org/10.1101/2022.01.11.22269045 
  26. Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. 2022;S0140-6736(22)00017-4.  https://doi.org/10.1016/S0140-6736(22)00017-4 
Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Dirk+Eggink&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Eggink Dirk</a>, <a href="/search?value1=Stijn+P+Andeweg&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Andeweg Stijn P</a>, <a href="/search?value1=Harry+Vennema&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Vennema Harry</a>, <a href="/search?value1=Noortje+van+Maarseveen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">van Maarseveen Noortje</a>, <a href="/search?value1=Klaas+Vermaas&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Vermaas Klaas</a>, <a href="/search?value1=Boris+Vlaemynck&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Vlaemynck Boris</a>, <a href="/search?value1=Raf+Schepers&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Schepers Raf</a>, <a href="/search?value1=Arianne+B+van+Gageldonk-Lafeber&option1=author&noRedirect=true" class="nonDisambigAuthorLink">van Gageldonk-Lafeber Arianne B</a>, <a href="/search?value1=Susan+van+den+Hof&option1=author&noRedirect=true" class="nonDisambigAuthorLink">van den Hof Susan</a>, <a href="/search?value1=Chantal+BEM+Reusken&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Reusken Chantal BEM</a>, <a href="/search?value1=Mirjam+J+Knol&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Knol Mirjam J</a></span>. Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022. <a href="/content/ecdc">Euro Surveill.</a> 2022;27(4):pii=2101196. <a href="https://doi.org/10.2807/1560-7917.ES.2022.27.4.2101196" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2022.27.4.2101196</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 29 Dec 2021;&nbsp;&nbsp; <span class="generated">Accepted</span>: 27 Jan 2022 </span> </p>
/content/10.2807/1560-7917.ES.2022.27.4.2101196
/content/10.2807/1560-7917.ES.2022.27.4.2101196
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error